Editas Medicine Inc (EDIT) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Editas Medicine Inc   (NASDAQ: EDIT)


Editas Medicine Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Editas Medicine Inc 's ROA in the second quarter of 2026?
Editas Medicine Inc recorded a cumulative net loss of $-74 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -37.56%.

However, within the Healthcare sector 472 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4011, from total ROA ranking in the first quarter of 2026 at 4834.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 17.46 % -43.36 % -44.61 % -38.41 % -45.26 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -74 -109 -160 -200 -237
Return On Assets (TTM) -37.56 % -58.04 % -74 % -78.55 % -82.86 %
EDIT's Total Ranking # 4011 # 4834 # 4281 # 4364 # 4391
Total Assets (TTM) in million 247 149 189 202 211
Seq. Total Assets Change 65.62 % -21.07 % -6.22 % -4.19 % -20.13 %
Seq. Net Income Change - - - - -

EDIT's 5 Years Annual ROA >> Back to EDIT Management Effectiveness >> Compare EDIT ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 55
Sector # 473
Overall # 3728

Return On Assets Statistics
High Average Low
-16.38 %
-38.67 %
-82.86 %
(Sep 30 2020)   (Jun 30 2025)



  News about Editas Medicine Inc Return on Assets ROA

Editas Medicine: Balancing the Future of Gene Editing with Strategic Financial Maneuvers Amidst Industry Challenges,

Editas Medicine: Navigating Financial Challenges while Pioneering Gene Editing SolutionsIn an ever-evolving biotechnology landscape, Editas Medicine Inc. is making strides both in clinical advancements and financial strategy. The company recently announced significant progress towards its 2024 goals, revealing pivotal developments in its quest to treat genetic disorders such as sickle cell disease and beta thalassemia. This article will outline the key facts from their recent press releases and financial performance metrics to provide a comprehensive overview of Editas Medicine s current position. Progress in Gene EditingEditas Medicine has achieved a critical milestone by obtaining in vivo preclinical proof of concept for hematopoietic stem and progenitor cell editing. Utilizing its proprietary targeted lipid nanoparticle (LNP) technology, the company aims to develop innovative in vivo treatments. This achievement marks a significant step forward in their goal to provide effective therapies for debilitating genetic conditions such as sickle cell disease and beta thalassemia, further establishing Editas as a front runner in the field of gene editing.



Financial Statements
Editas Medicine Inc 's Assets $ 247 million EDIT's Balance sheet
Editas Medicine Inc 's Income $ -18 million Quarterly EDIT's Income Statement
EDIT's Income by Division See EDIT's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -45.39 % -31.67 % -3.01 % -23.92 % 18.32 %
Total Assets in million 187 342 500 515 677
Y / Y Net Income Change - - - - -
Net Income in million -160 -237 -153 -220 -193
Annual Return On Assets -85.81 % -69.41 % -30.65 % -42.77 % -28.41 %

EDIT's 5 Years Annual ROA >> Back to EDIT Management Effectiveness >> Compare EDIT ROA to its Competitors



More Return On Assets Ratios
EDIT's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
EDIT's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for EDIT's Competitors
Subscribers only: Roa for Editas Medicine Inc 's Suppliers
Subscribers only: Return On Assets for EDIT's Customers

You may also want to know
EDIT's Roi EDIT's Inventory Turnover Ratio EDIT's Growth Rates EDIT's Dividend Comparisons
EDIT's Profitability Ratios EDIT's Asset Turnover Ratio EDIT's Dividend Growth
EDIT's Roe EDIT's Valuation Ratios EDIT's Financial Strength Ratios EDIT's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-08T17:29:50+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.